Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 3
Chunk 4
---
 have a negative impact on the commercialization of our current products and delay or prevent development or commercialization of our product candidates.

•As part of our strategy, we have obtained rights to vaccine candidates or technology from other parties, and we may acquire or obtain rights to other vaccine candidates or technology in the future. Any such agreements or transactions may not result in any of the benefits anticipated from such arrangements, which could adversely affect our ability to develop and commercialize potential future products.

40

•Our stock price is subject to volatility, and your investment may suffer a decline in value. 

•Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock price to fall.

•Servicing our Convertible Notes requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt. Conversion of the Convertible Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.

•The loss of key personnel could delay or prevent achieving our objectives. In addition, our continued growth to support commercialization may result in difficulties in managing our growth and expanding our operations successfully.

•If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.

Risks Related to our Business and Capital Requirements

HEPLISAV-B faces significant competition in the U.S., the only geographic region in which we currently market it. Since this is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we may not achieve and sustain commercial success for HEPLISAV-B.*

We have established sales, marketing and distribution capabilities and commercialized HEPLISAV-B in the U.S. We have also received approval in the EU and the UK for HEPLISAV-B. Successful commercialization of HEPLISAV-B in these regions or elsewhere, to the extent we pursue such efforts, will require significant resources and time, and there can be no certainty that we will succeed in these efforts. While our personnel are experienced with respect to marketing of healthcare products, because HEPLISAV-B is our first marketed product, the potential uptake of the product through distribution, and the timing, trajectory, rate and sustainability for growth